Insights on the Tigris Trial from Spectral Medical
TORONTO, September 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a prominent company focused on enhancing treatment options for sepsis and septic shock, has provided an update on its Tigris trial. This Phase 3 follow-up study aims to assess the effectiveness of Polymyxin B Hemoperfusion (PMX) in treating adults suffering from endotoxemia and septic shock.
Tigris Trial Enrollment Progress
The trial has experienced robust enrollment as we move through the latter half of 2024, maintaining a steady pace that has been evident since the start of the year:
Current Enrollment Statistics
As of the end of August 2024, a total of 129 patients have joined the Tigris trial. Remarkably, even during August—a month typically slower for clinical trials—four patients were successfully enrolled. So far in 2024, the trial has seen 48 patients enrolled, representing the highest recruitment rate since the Tigris study began.
Final Enrollment Goals
With just 21 patients left to reach full enrollment, Spectral is entering a critical final phase of the Tigris trial. Current trends indicate that the trial could wrap up by December 2024, marking a significant achievement in their research efforts.
Dr. John Kellum, Chief Medical Officer of Spectral, expressed his satisfaction with the trial's progress, stating, “It’s encouraging to witness strong enrollment over the summer months. Our sites are performing exceptionally well, and we are optimistic about concluding full enrollment by the end of 2024.”
Vantive-Carlyle Group Transaction
On August 13, 2024, Baxter International announced a definitive agreement with The Carlyle Group to divest its Vantive business. This arrangement, known as the Vantive-Carlyle transaction, is expected to have favorable implications for Spectral Medical. Following the completion of this deal, which is anticipated by late 2024 or early 2025, Spectral's distribution agreement for PMX with Baxter will transfer to Vantive.
Positive Outlook for Spectral
Chris Seto, Chief Executive Officer of Spectral, commented on the significance of the transaction, stating, “The Carlyle Group's involvement marks a positive chapter for Spectral. They bring substantial private equity expertise in medical technologies, with over $40 billion in investments. While Vantive's ownership will change, we expect their strategy regarding EAA and PMX to remain strong, ensuring effective commercialization efforts.”
Understanding Spectral Medical
Spectral Medical is committed to obtaining U.S. FDA approval for its innovative Toraymyxin™ (PMX), a therapeutic device designed to remove endotoxins from the body, which are responsible for sepsis. The company’s technology is supported by its proprietary Endotoxin Activity Assay (EAA™), currently the only FDA-cleared diagnostic tool for assessing sepsis risk.
Proven Efficacy and Expansion Plans
PMX is already approved for use in Japan and Europe, demonstrating safety and effectiveness in over 340,000 patients. In March 2009, Spectral secured exclusive rights for PMX's development and commercialization in the U.S., followed by an exclusive distribution agreement in Canada in November 2010. Notably, in July 2022, the FDA designated PMX as a Breakthrough Device, recognizing its potential in treating endotoxic septic shock, a condition that impacts around 330,000 individuals annually in North America.
About the Tigris Trial
The Tigris trial serves as a confirmatory assessment of PMX compared to standard care alone, involving a randomized trial with 150 patients and utilizing Bayesian statistical methods. This study aims to demonstrate the efficacy of PMX in addressing this aggressive form of sepsis.
Frequently Asked Questions
What is the Tigris trial about?
The Tigris trial is a Phase 3 study that evaluates the effectiveness of PMX in patients suffering from septic shock, in comparison to standard care.
Who is leading the Tigris trial?
The trial is being conducted by Spectral Medical Inc., under the direction of their Chief Medical Officer, Dr. John Kellum.
What are the recent enrollment figures for the trial?
As of August 2024, a total of 129 patients have been enrolled, with strong recruitment continuing throughout the year.
What is the significance of the Vantive-Carlyle transaction?
This transaction is expected to strengthen Spectral’s market position, facilitating a transition in PMX distribution to a company with significant financial resources.
What is PMX and its current status?
PMX is a therapeutic device that targets endotoxins in the bloodstream and has received approval for use in several markets, with ongoing efforts to secure FDA approval in the U.S.
